AMAG Pharmaceuticals, Inc.
AMAG - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-13.71 |
| Beta | - |
| Outstanding Shares | 34,484,000 |
Return
| Return on Equity | -89.51% |
|---|---|
| Return on Assets | -31.21% |
| Return on Invested Capital | -6.29% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | 1.13 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About AMAG Pharmaceuticals, Inc.
440 employees
CEO: Scott D. Myers
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commerci...